Related posts

Sell-off continues, Bitcoin downRally continues after more tame inflation dataInvesting in Ozempic Stocks – Unlocking the Stock Price Growth Potential
Investor Insights

This summary was created by AI, based on 42 opinions in the last 12 months.

The consensus among different experts about Eli Lilly & Co. seems to be that the company has a strong focus on developing drugs for obesity, diabetes, Alzheimer's, and other ailments, with potential for significant market growth. However, there is concern about the high valuation of the stock, with a forward PE ratio of around 50x earnings. Some experts also highlight the need for further validation of the long-term effects of the weight-loss drugs and other products. Overall, there is optimism about the company's growth potential, but caution about the current valuation and risk factors.

Consensus
Mixed
Valuation
Overvalued
HOLD
Eli Lilly & Co.
Upgraded today

Agrees with this call. Obesity drugs remain a big opportunity within healthcare, a $100-billion market by 2030, says Goldman; half the world's population would qualify by then. True, LLY is expensive at 55x forward PE, he still likes and owns this. He may trim at a higher price.

biotechnology / pharmaceutical
COMMENT
Eli Lilly & Co.
Upgraded today

Their popular obesity drug is like AI--a lot is already priced in, though the obesity drug may be applicable to other ailments.

biotechnology / pharmaceutical
SELL
Eli Lilly & Co.

Big difference between a company and a stock. It's like buying a jacket for different price points of $1000, $300, or on sale for $150. You make an investment/purchase decision. 

LLY and NVO are great companies, but you have to look at how expensive they are. Quite expensive at around 50x earnings. Good growth rates. A reasonable multiple for a drug company is sub-20x, and these won't get there via discounted cashflow until next decade. That's a long way out.

He looks for things that have yet to be priced properly. He owns MRK.

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.
Upgraded today

The fundamental story is compelling, enjoying momentum and a technical breakout, but it could pause before it resumes its climb.

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.

A drug approval was delayed and shares are down only 2% today. If there's a market correction, LLY will also fall. But their fundamental story has not changed and he still believes in it.

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.

Was upgraded today. It trades like a biotech. The response to their strong earnings on Feb. 6 has been purely positive, rallying. The catalyst are the momentum funds buying this which have a 5% weighting in LLY. Also, the fundamentals are in place.

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.

There's a huge market for the weight-loss drug. Also, LLY has a strong drug pipeline: ulcerative colitis, Alzheimer's, for instance. 

biotechnology / pharmaceutical
DON'T BUY
Eli Lilly & Co.

Appreciates what it's done. Trades north of 50x current earnings, expected growth rate is pretty exciting. Ask yourself: is it worth paying up, when peers are trading around 15x? He'd look at AMGN.

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.

It reports Tuesday. It comes down to their weight-loss drug sales. How quickly can they rump in production of it in their factories to meet demand?

biotechnology / pharmaceutical
PARTIAL BUY
Eli Lilly & Co.
Entry point?

Is up 83% in the past year. Their hit weight-loss drug is in such demand that you can't find it in New York City. Buy some tomorrow, then buy more at a 5% downturn.

biotechnology / pharmaceutical
BUY ON WEAKNESS
Eli Lilly & Co.

Excellent business, but would wait for share price weakness before buying. Performance has made shares expensive. Weight loss drugs performing very well. One concern is that weight loss drugs are unproven. 

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.

They make key drugs for obesity and diabetes. Shares rallied strong last year and continue to do so.

biotechnology / pharmaceutical
WAIT
Eli Lilly & Co.

High PE. Huge expectations baked into the price. Long-term effects of these weight-loss drugs are not yet proven. Any hiccup or negative news will slam the stock, and that might be your entry point.

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.

He should have deemed this a buy, don't trade stock, but he wasn't sure about their latest drug test results. Turns out that those results were fine. he got that call wrong.

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.

They have the best model among pharma, spending years to develop their drug pipeline, like their weight-loss drug. Their superior research is their secret sauce. They don't have a patent cliff like their peers. They are a growth name without buying other companies.

biotechnology / pharmaceutical
Showing 1 to 15 of 113 entries

Eli Lilly & Co.(LLY-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 24

Neutral - Hold Signals / Votes : 3

Bearish - Sell Signals / Votes : 7

Total Signals / Votes : 34

Stockchase rating for Eli Lilly & Co. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Eli Lilly & Co.(LLY-N) Frequently Asked Questions

What is Eli Lilly & Co. stock symbol?

Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N

Is Eli Lilly & Co. a buy or a sell?

In the last year, 34 stock analysts published opinions about LLY-N. 24 analysts recommended to BUY the stock. 7 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Eli Lilly & Co..

Is Eli Lilly & Co. a good investment or a top pick?

Eli Lilly & Co. was recommended as a Top Pick by on . Read the latest stock experts ratings for Eli Lilly & Co..

Why is Eli Lilly & Co. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Eli Lilly & Co. worth watching?

34 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.

What is Eli Lilly & Co. stock price?

On 2024-03-18, Eli Lilly & Co. (LLY-N) stock closed at a price of $762.66.